Columbia Engineering researchers report that Sofosbuvir-terminated RNA is more resistant to the proofreader of SARS-CoV-2, the virus that causes COVID-19, than Remdesivir-terminated RNA. The results of the new study, published today by the Nature Research journal Scientific Reports, support the use of the FDA-approved hepatitis C drug EPCLUSA—Sofosbuvir/Velpatasvir—in combination with other drugs in COVID-19 clinical trials.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.
Rush University Medical Center is recruiting participants for a nationwide trial of a COVID-19 vaccine developed by the University of Oxford in England and AstraZeneca, a multinational pharmaceutical company.
As the global response to the SARS-COV-2 virus that causes COVID-19 approaches 200 days, Baylor Scott & White Research Institute, the research and development arm of Baylor Scott & White Health, is accelerating its pace of bringing clinical trials online.
Baylor Scott & White Research Institute continues to mobilize staff and resources, including components needed to integrate critical patient-safety measures at every participating site within the Baylor Scott & White system for industry sponsored drug trials, investigator-initiated drug trials and research studies, and observational and data studies designed to help increase knowledge around case trends, viral epidemiology, and care best practices.
Mount Sinai and Emergent to conduct clinical trials to evaluate COVID-HIG for post-exposure prophylaxis of COVID-19 in front-line health care workers and to support a potential Expanded Access Program for military personnel with funding from the U.S. Department of Defense
– ImmunoTek to extend operating license and provide training to Mount Sinai to establish onsite plasma collection to support production of COVID-HIG
Rush University Medical Center has opened enrollment for a new clinical trial investigating whether the drug hydroxychloroquine is better than a placebo in preventing COVID-19 infection in healthy people working in health care settings.
As a leading New Jersey academic medical center and member of Hackensack Meridian Health, Jersey Shore University Medical Center is able to provide its patients access to existing clinical trials and the latest medical techniques in a variety of specialties. Currently, the medical center is recruiting individuals who have been clinically diagnosed with COVID-19 or have laboratory test results showing they have COVID-19 antibodies to donate their blood and potentially assist patients in their recovery from the virus.
It seems as though there will never be enough “thank-you’s” for the incredible doctors, nurses, technicians and support staff who are working around the clock to help patients with this dangerous coronavirus disease. It’s their dedication, determination and spirit that enable Johns Hopkins to deliver the promise of medicine.